Cuorips Inc.
Cuorips is an Osaka-based regenerative-medicine company listed on the TSE Growth market (4894). Its iPS cell-derived heart muscle sheet RiHEART received conditional, time-limited approval in Japan in March 2026.
| Headquarters | Osaka, Japan |
|---|---|
| Listing | TSE Growth:4894 |
| Lead asset / stage | RiHEART Conditionally approved — Japan (time-limited) |
| Latest event | Cuorips announced an NHK programme featuring the company, scheduled for November 7, 2026. |